<p><h1>Human Cytomegalovirus Envelope Glycoprotein B Market Size: Growth Outlook from 2024 to 2031, projecting at Market's Trends Analysis by Application, Regional Outlook, and Revenue</h1></p><p><strong>Human Cytomegalovirus Envelope Glycoprotein B Market Analysis and Latest Trends</strong></p>
<p><p>Human Cytomegalovirus Envelope Glycoprotein B (gB) is a protein found on the surface of the human cytomegalovirus (HCMV) that plays a key role in virus entry into host cells. It is considered a potential target for antiviral therapies and vaccine development against HCMV infections.</p><p>The Human Cytomegalovirus Envelope Glycoprotein B Market is expected to witness significant growth in the coming years, with a projected CAGR of 11.4% during the forecast period. Factors driving this growth include the rising prevalence of HCMV infections, increasing awareness about the potential of gB as a therapeutic target, and ongoing research and development activities in the field of antiviral drugs and vaccines.</p><p>Market trends include collaborations between pharmaceutical companies and research institutions to develop novel therapies targeting gB, increasing investment in HCMV research, and the growing focus on personalized medicine approaches for HCMV treatment. Additionally, the market is expected to benefit from advancements in biotechnology and immunotherapy, which are opening up new opportunities for targeting gB in HCMV-infected individuals.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1839228">https://www.reliableresearchreports.com/enquiry/request-sample/1839228</a></p>
<p>&nbsp;</p>
<p><strong>Human Cytomegalovirus Envelope Glycoprotein B Major Market Players</strong></p>
<p><p>The Human Cytomegalovirus Envelope Glycoprotein B (HCMV gB) market is highly competitive with key players such as Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc, and Vical Incorporated leading the market. </p><p>Astellas Pharma Inc. is a Japanese pharmaceutical company that is actively involved in research and development of various therapies, including vaccines for infectious diseases such as HCMV. The company has shown significant market growth over the years and is expected to continue its growth trajectory in the coming years.</p><p>VBI Vaccine Inc. is a biopharmaceutical company focused on developing vaccines for a range of infectious diseases, including HCMV. The company has a strong pipeline of vaccine candidates and has shown promising results in clinical trials, indicating potential future growth in the market.</p><p>Vical Incorporated is a biopharmaceutical company that specializes in the development of DNA-based vaccines and gene therapies. The company has been actively working on vaccine candidates for HCMV and has shown steady growth in the market.</p><p>The sales revenue of these companies varies, with Astellas Pharma Inc. being one of the top players in terms of revenue. However, all these companies have shown steady growth and have a promising future in the HCMV gB market as they continue to focus on research and development of innovative therapies and vaccines.</p><p>Overall, the HCMV gB market is competitive, with key players such as Astellas Pharma Inc., VBI Vaccine Inc, and Vical Incorporated leading the way in research and development of vaccines for HCMV. These companies are expected to drive market growth in the coming years with their innovative approaches and strong pipeline of vaccine candidates.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Human Cytomegalovirus Envelope Glycoprotein B Manufacturers?</strong></p>
<p><p>The Human Cytomegalovirus Envelope Glycoprotein B market is expected to experience significant growth in the coming years due to the rising prevalence of cytomegalovirus infections worldwide. Key factors driving market growth include the increasing awareness about the disease, advancements in diagnostic technologies, and the development of novel treatment options. The market is also likely to benefit from the growing healthcare expenditure, supportive government initiatives, and expanding research and development activities. Overall, the Human Cytomegalovirus Envelope Glycoprotein B market is poised for a positive outlook with increasing demand for effective diagnostic and therapeutic solutions.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1839228">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1839228</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Human Cytomegalovirus Envelope Glycoprotein B Market Analysis by types is segmented into:</strong></p>
<p><ul><li>CSJ-148</li><li>CyMVectin</li><li>TRL-345</li><li>PPCM</li><li>Cytomegalovirus Vaccine</li><li>Others</li></ul></p>
<p><p>The Human Cytomegalovirus Envelope Glycoprotein B Market includes various types such as CSJ-148, CyMVectin, TRL-345, PPCM, Cytomegalovirus Vaccine, and others. CSJ-148 is a novel antiviral compound, CyMVectin is a vector-based vaccine, TRL-345 is a therapeutic vaccine, PPCM is a possible treatment for congenital CMV infection, and Cytomegalovirus Vaccine is a preventative option. Other products in the market include different antiviral medications, vaccines, and treatment options aimed at combating Human Cytomegalovirus infection.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1839228">https://www.reliableresearchreports.com/purchase/1839228</a></p>
<p>&nbsp;</p>
<p><strong>The Human Cytomegalovirus Envelope Glycoprotein B Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Infectious Disease</li><li>Oncology</li><li>Women's Health</li><li>Others</li></ul></p>
<p><p>Human Cytomegalovirus Envelope Glycoprotein B holds potential in various markets including Infectious Disease, Oncology, Women's Health, and Others. In Infectious Disease, it can be used for the treatment of CMV infections. In Oncology, it may be utilized for cancer immunotherapy. In Women's Health, it could aid in the prevention of congenital CMV infections during pregnancy. The glycoprotein B also has potential applications in other medical fields, such as transplantation and autoimmune diseases.</p></p>
<p><a href="https://www.reliableresearchreports.com/human-cytomegalovirus-envelope-glycoprotein-b-r1839228">&nbsp;https://www.reliableresearchreports.com/human-cytomegalovirus-envelope-glycoprotein-b-r1839228</a></p>
<p><strong>In terms of Region, the Human Cytomegalovirus Envelope Glycoprotein B Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The Human Cytomegalovirus Envelope Glycoprotein B market is expected to witness significant growth in North America, Europe, USA, and China, driven by factors such as increasing research and development activities in the field of virology and rising prevalence of cytomegalovirus infections. Among these regions, North America is anticipated to dominate the market with a market share of 35%, followed by Europe with 30%, USA with 20%, and China with 15%. The APAC region is also expected to witness steady growth in the market.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1839228">https://www.reliableresearchreports.com/purchase/1839228</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1839228">https://www.reliableresearchreports.com/enquiry/request-sample/1839228</a></p>
<p><strong></strong></p>
<p><p><a href="https://github.com/rick7624/Market-Research-Report-List-1/blob/main/245217257553.md">가축 사료 보충제</a></p><p><a href="https://github.com/lubmix/Market-Research-Report-List-2/blob/main/bacillary-dysentery-drug-market.md">Bacillary Dysentery Drug Market</a></p><p><a href="https://github.com/Hazelklievgspy6vdcsmu106w/Market-Research-Report-List-2/blob/main/granulomatosis-with-polyangiitis-drug-market.md">Granulomatosis with Polyangiitis Drug Market</a></p><p><a href="https://issuu.com/reportprime-2/docs/vanadium-pentoxide-for-electrolyte-of-vanadium-bat">Vanadium Pentoxide for Electrolyte of Vanadium Battery Market</a></p></p>